{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:11:43Z","timestamp":1789668703595,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coi.2026.102842","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:57:01Z","timestamp":1789667821000},"page":"102842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical relevance of antiphosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-139X","authenticated-orcid":false,"given":"Maria Laura","family":"Bertolaccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2830-3087","authenticated-orcid":false,"given":"Giovanni","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102842_sbref1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102842_sbref2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102842_bib4","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2","article-title":"Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant","volume":"43","author":"Atsumi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102842_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","author":"Bertolaccini","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Subcommittee on Lupus Anticoagulant\/Antiphospholipid A. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.thromres.2018.11.003","article-title":"Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns","volume":"172","author":"Pengo","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102842_bib8","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1021\/bi00393a033","article-title":"Nucleotide sequence of the gene for human prothrombin","volume":"26","author":"Degen","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.coi.2026.102842_bib9","doi-asserted-by":"crossref","first-page":"18927","DOI":"10.1016\/S0021-9258(18)55152-8","article-title":"Characterization of a novel liver-specific enhancer in the human prothrombin gene","volume":"266","author":"Chow","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2026.102842_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fmed.2018.00281","article-title":"Structure of coagulation factor II: molecular mechanism of thrombin generation and development of next-generation anticoagulants","volume":"5","author":"Chinnaraj","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2026.102842_bib12","first-page":"237","article-title":"Prothrombin as a co-factor of the circulating anticoagulant in systemic lupus erythematosus?","volume":"3","author":"Loeliger","year":"1959","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.coi.2026.102842_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood.V15.2.212.212","article-title":"A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity","volume":"15","author":"Rapaport","year":"1960","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V61.4.684.684","article-title":"A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome","volume":"61","author":"Bajaj","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V64.4.807.807","article-title":"Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors","volume":"64","author":"Edson","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/blood.V72.2.512.512","article-title":"Anti-prothrombin antibodies and the lupus anticoagulant","volume":"72","author":"Fleck","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib18","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood.V81.10.2618.2618","article-title":"Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?","volume":"81","author":"Oosting","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1055\/s-0038-1649891","article-title":"Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants","volume":"74","author":"Arvieux","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib20","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.V93.7.2149","article-title":"Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome","volume":"93","author":"Galli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib21","first-page":"S281","article-title":"Anti-plasma protein antibodies are predictive of thrombotic events","volume":"37","author":"Petri","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102842_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/clin.1996.0089","article-title":"Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus","volume":"80","author":"Puurunen","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.coi.2026.102842_bib23","first-page":"1104","article-title":"Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus","volume":"25","author":"Bertolaccini","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102842_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0038-1650355","article-title":"Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid reactive antibodies","volume":"75","author":"Pengo","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-0038-1655994","article-title":"Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies","volume":"77","author":"Galli","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11926-014-0415-x","article-title":"New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies","volume":"16","author":"Sciascia","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coi.2026.102842_bib27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2019030932","article-title":"Discovery and characterization of 2 novel subpopulations of aPS\/PT antibodies in patients at high risk of thrombosis","volume":"3","author":"Chinnaraj","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102842_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102641","article-title":"Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome","volume":"19","author":"Sciascia","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102842_bib29","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood.V84.9.2854.2854","article-title":"Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other antiphospholipid autoantibodies","volume":"84","author":"Roubey","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102842_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.2006.06283.x","article-title":"A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells","volume":"135","author":"Vega-Ostertag","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2026.102842_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1998.00562.x","article-title":"Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction","volume":"100","author":"Puurunen","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2026.102842_bib32","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jth.14551","article-title":"Antiphosphatidylserine\/prothrombin complex antibodies as a determinant of prothrombotic plasma fibrin clot properties in patients with antiphospholipid syndrome","volume":"17","author":"Zabczyk","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib33","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/jth.15320","article-title":"Antiprothrombin antibodies induce platelet activation: a possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?","volume":"19","author":"Chayoua","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1191\/0961203303lu370oa","article-title":"Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model","volume":"12","author":"Haj-Yahja","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102842_bib35","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/rheumatology\/ket234","article-title":"Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody","volume":"52","author":"Oku","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102842_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13317-019-0113-9","article-title":"Anti-beta2-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells","volume":"10","author":"Cifu","year":"2019","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.coi.2026.102842_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","author":"Sciascia","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib38","first-page":"S9","article-title":"Antibodies to phosphatidylserine\/prothrombin (aPS\/PT) are an independent risk factor for thrombosis in patients with systemic lupus erythematosus (SLE)","volume":"63","author":"Bertolaccini","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102842_bib39","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/jth.12014","article-title":"Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities","volume":"10","author":"Sciascia","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0961203314538332","article-title":"Antibodies to phosphatidylserine\/prothrombin complex and the antiphospholipid syndrome","volume":"23","author":"Sciascia","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102842_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/724592","article-title":"Detection of antiphosphatidylserine\/prothrombin antibodies and their potential diagnostic value","volume":"2013","author":"Zigon","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.coi.2026.102842_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fneur.2012.00137","article-title":"Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a TIA cohort","volume":"3","author":"Mullen","year":"2012","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2026.102842_bib43","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102842_bib44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0040-1705115","article-title":"Antiphosphatidylserine\/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome","volume":"120","author":"Radin","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/975704","article-title":"Anti-phosphatidylserine\/prothrombin antibodies are associated with adverse pregnancy outcomes","volume":"2015","author":"Zigon","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.coi.2026.102842_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1515\/cclm-2017-0502","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome","volume":"56","author":"Shi","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.coi.2026.102842_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13621","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) and risk of obstetric anti-phospholipid syndrome","volume":"89","author":"Zhang","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2026.102842_bib48","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/jth.15053","article-title":"The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities","volume":"18","author":"Foddai","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib49","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/jcm10102094","article-title":"Anti-phosphatidylserine\/prothrombin antibodies in healthy women with unexplained recurrent pregnancy loss","volume":"10","author":"Pleguezuelo","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102842_bib50","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1136\/rmdopen-2020-001340","article-title":"Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study","volume":"6","author":"Abisror","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102842_bib51","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1515\/cclm-2014-1129","article-title":"Relationship between antiphosphatidylserine\/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome","volume":"53","author":"Hoxha","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.coi.2026.102842_bib52","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3899\/jrheum.170044","article-title":"Closing the serological gap in the antiphospholipid syndrome: the value of \u201cnon-criteria\u201d antiphospholipid antibodies","volume":"44","author":"Zohoury","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102842_bib53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10067-018-4301-1","article-title":"Study of clinical utility of antibodies to phosphatidylserine\/prothrombin complex in Asian-Indian patients with suspected APS","volume":"38","author":"Ganapati","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2026.102842_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_sbref55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/cei\/uxae079","article-title":"Antibody profiles in the mosaic of 'seronegative' APS syndrome","volume":"218","author":"Truglia","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2026.102842_bib56","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/keab414","article-title":"Non-criteria antiphospholipid antibodies': bridging the gap between seropositive and seronegative antiphospholipid syndrome","volume":"61","author":"Truglia","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102842_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.621590","article-title":"Incidence of a first thrombo-embolic event in patients with systemic lupus erythematosus and anti-phosphatidylserine\/prothrombin antibodies: a prospective study","volume":"8","author":"Sciascia","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2026.102842_bib58","first-page":"S3","article-title":"Prospective validation of the Global AntiPhospholpid Syndrome Score (GAPSS)","volume":"65","author":"Sciascia","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102842_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2019.03.006","article-title":"IgG phosphatidylserine\/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers","volume":"177","author":"Tonello","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102842_bib60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102842_bib61","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib62","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1055\/s-0037-1615066","article-title":"The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity \u2014 discrimination between functional and non-functional anti-prothrombin-antibodies","volume":"79","author":"Horbach","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.2001.02950.x","article-title":"Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus","volume":"114","author":"Nojima","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2026.102842_bib64","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/jth.14896","article-title":"Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome","volume":"18","author":"Pengo","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_bib65","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jth.14765","article-title":"Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity","volume":"18","author":"Cattini","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_sbref66","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jth.15785","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_sbref67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102842_bib68","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jth.15792","article-title":"Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population","volume":"20","author":"Pham","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102842_sbref69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1636171","article-title":"Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome","volume":"16","author":"Cabrera-Marante","year":"2025","journal-title":"Front Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:57:10Z","timestamp":1789667830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526001196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":69,"alternative-id":["S0952791526001196"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102842","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of antiphosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102842"}}